COHANCENSECohance Lifesciences Limited· Pharmaceuticals & BiotechnologyHighNegative
Announced Thu, 18 Sept, 2025 · 19:26 IST

Promoter sells 3.41 crore shares, reducing stake to 24.15%

Promoter Stake Sell 1pctPromoter Below 50pctOwnership Changes View source PDFExplain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.4%Reaction day
₹909.80
prior close
₹910.00
announcement price
After-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%-0.5% vs market
Pharmaceuticals peers, median of 153sector+0.1%-0.5% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Smallcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.5
10m
+0.5
15m
+0.6
30m
+0.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.4+0.1-0.5+0.1-0.5
Next day
-0.6-0.8+0.2-0.8+0.2
2d
-1.1-1.3+0.2-0.9-0.1
3d
-0.4-1.8+1.4-1.2+0.8
4d
-2.0-2.5+0.5-2.3+0.3
5d
-5.1-4.6-0.6-4.1-1.1
1w
-3.6-4.5+0.9-4.2+0.6
15d
-2.6-2.4-0.2-3.5+0.9
1m
-3.5-1.8-1.7-3.5+0.0
2m
-35.9-3.0-32.8-6.3-29.5
3m
-41.0-6.1-34.8-8.6-32.4
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Promoter Jusmiral Holdings sold 34,148,000 Cohance shares on the NSE on September 18, 2025. The transaction was worth Rs 3,093.81 crore before costs, and the promoter's holding fell from 33.08% to 24.15%, a drop of 8.93 percentage points. Proceeds will mainly repay borrowings under a notes purchase agreement.

Likely market impact

The promoter's large share sale may add near-term price pressure, while debt repayment from proceeds may reduce financing risk.